<DOC>
	<DOCNO>NCT00212602</DOCNO>
	<brief_summary>The purpose study examine efficacy safety ONO-7436 prevention cancer chemotherapy-induced nausea vomit patient malignant tumor</brief_summary>
	<brief_title>ONO-7436 Phase II Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<criteria>1 . Patients age 20 year old 2 . Patients malignant tumor intravenously administer cisplatin single dose 70 mg/m2 3 hour 3 . Patients whose performance status 0 2 4 . Other inclusion criterion specify study protocol 1 . In case patient previously treat cisplatin , past history vomit administration cisplatin 2 . Patients vomit dry vomit within 24 hour initial administration moderate severe emetic chemotherapy ( include cisplatin ) Day 1 study 3 . Pregnant woman , nurse woman , woman childbearing potential , woman wish become pregnant woman use oral contraception 4 . Other exclusion criterion specify study protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-7436 , Aprepitant , Vomiting , Nausea</keyword>
</DOC>